To access this element change to forms mode OFF
Grant Award View - GA187305
AdaptiVax-CoV: A novel adaptable SARS-CoV2 VLP vaccine to produce broad...
GA ID:
GA187305
Agency:
Department of Health and Aged Care
Approval Date:
16-Jun-2021
Publish Date:
30-Aug-2021
Category:
Health and Medical Research
Grant Term:
16-Jun-2021 to 31-May-2023
Value (AUD):
$2,999,862.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 20/21 1.1 Health Policy Research and Analysis
Grant Program:
2020_MRFF_COVID-19_Vaccine_Candidate_Research_R3
Grant Activity:
AdaptiVax-CoV: A novel adaptable SARS-CoV2 VLP vaccine to produce broad humoral and T cell responses to S, E and M viral proteins
Purpose:
In response to the COVID-19 pandemic over 20 vaccines are in clinical trials to test if these 'first generation' vaccines are safe and effective. However, whilst these vaccines may prove to be efficacious, they will only produce limited immune responses that will fail to protect against emerging coronaviruses. Accordingly, we have developed a significantly novel vaccine candidate that will produce broadly protective responses not only for COVID-19 but also future coronavirus global threats.
GO ID:
GO Title:
MRFF – 2020 COVID-19 Vaccine Candidate Research grant opportunity
Internal Reference ID:
MRF2013957
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, VIC, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, NEW ZEALAND